Troy Wichterman Sells 877 Shares of BioLife Solutions, Inc. (NASDAQ:BLFS) Stock

BioLife Solutions, Inc. (NASDAQ:BLFS - Get Free Report) CFO Troy Wichterman sold 877 shares of the business's stock in a transaction dated Monday, July 7th. The shares were sold at an average price of $22.27, for a total transaction of $19,530.79. Following the completion of the sale, the chief financial officer owned 185,808 shares in the company, valued at approximately $4,137,944.16. This trade represents a 0.47% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink.

Troy Wichterman also recently made the following trade(s):

• On Tuesday, June 10th, Troy Wichterman sold 1,042 shares of BioLife Solutions stock. The shares were sold at an average price of $23.70, for a total transaction of $24,695.40.
• On Wednesday, May 28th, Troy Wichterman sold 583 shares of BioLife Solutions stock. The stock was sold at an average price of $22.46, for a total value of $13,094.18.

BioLife Solutions Trading Down 3.4%

NASDAQ:BLFS traded down $0.77 on Friday, reaching $21.95. 266,696 shares of the company's stock were exchanged, compared to its average volume of 419,876. The company has a quick ratio of 3.74, a current ratio of 4.73 and a debt-to-equity ratio of 0.01. The firm has a market capitalization of $1.05 billion, a price-to-earnings ratio of -75.69 and a beta of 1.79. The business has a fifty day moving average of $22.38 and a 200-day moving average of $24.36. BioLife Solutions, Inc. has a 52-week low of $18.70 and a 52-week high of $29.55.

BioLife Solutions (NASDAQ:BLFS - Get Free Report) last announced its quarterly earnings data on Thursday, May 8th. The medical equipment provider reported $0.04 EPS for the quarter, topping analysts' consensus estimates of ($0.03) by $0.07. BioLife Solutions had a negative return on equity of 0.66% and a negative net margin of 11.81%. The business had revenue of $23.94 million during the quarter, compared to the consensus estimate of $22.22 million. As a group, analysts expect that BioLife Solutions, Inc. will post -0.3 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several equities analysts recently issued reports on the company. HC Wainwright reissued a "buy" rating and set a $30.00 target price on shares of BioLife Solutions in a research note on Tuesday, May 13th. Wall Street Zen lowered shares of BioLife Solutions from a "hold" rating to a "sell" rating in a research note on Wednesday, May 21st. One analyst has rated the stock with a sell rating and six have issued a buy rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average target price of $31.17.

Hedge Funds Weigh In On BioLife Solutions

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Sei Investments Co. grew its position in shares of BioLife Solutions by 0.5% during the first quarter. Sei Investments Co. now owns 117,999 shares of the medical equipment provider's stock worth $2,695,000 after buying an additional 547 shares in the last quarter. Rhumbline Advisers grew its position in shares of BioLife Solutions by 0.7% during the first quarter. Rhumbline Advisers now owns 83,227 shares of the medical equipment provider's stock worth $1,901,000 after buying an additional 566 shares in the last quarter. GAMMA Investing LLC grew its position in shares of BioLife Solutions by 18.6% during the first quarter. GAMMA Investing LLC now owns 4,223 shares of the medical equipment provider's stock worth $96,000 after buying an additional 663 shares in the last quarter. 1620 Investment Advisors Inc. grew its position in shares of BioLife Solutions by 41.7% during the fourth quarter. 1620 Investment Advisors Inc. now owns 2,295 shares of the medical equipment provider's stock worth $60,000 after buying an additional 675 shares in the last quarter. Finally, Comerica Bank grew its position in shares of BioLife Solutions by 5.2% during the first quarter. Comerica Bank now owns 15,024 shares of the medical equipment provider's stock worth $343,000 after buying an additional 746 shares in the last quarter. 93.24% of the stock is owned by institutional investors and hedge funds.

About BioLife Solutions

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.